爾康製藥(300267.SZ):磷酸氯喹原料藥通過CDE審批
格隆匯2月23日丨爾康製藥(300267.SZ)公佈,2020年2月21日,公司從國家藥品監督管理局藥品審評中心(CDE)“原料藥、藥用輔料和藥包材登記信息公示”平台查詢獲悉,全資子公司湖南湘易康製藥有限公司(“湘易康”)提交的“磷酸氯喹”原料藥(受理號:CYHT1600548)通過了CDE審批。
磷酸氯喹用於治療對氯喹敏感的惡性瘧、間日瘧等瘧疾,也可用於腸外阿米巴病的治療,還具有抗風濕等作用。
2020年2月19日,國家衞生健康委員會印發新型冠狀病毒肺炎診療方案(試行第六版),磷酸氯喹作為抗病毒治療的試用藥物已被納入該版診療方案。公司根據國家應對新型冠狀病毒感染的肺炎疫情防治所需應急物資生產供應和保障的要求,加快推動“磷酸氯喹”原料藥補充申請的審批,積極履行社會責任,為疫情防治貢獻力量。
“磷酸氯喹”原料藥通過CDE審批,有利於加快公司“磷酸氯喹”原料藥產業佈局,進一步豐富公司原料藥品種,完善原料藥產品結構,為公司構建“原輔料+製劑一體化”商業生態提供更多支持。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.